IPSC Century Therapeutics, Inc.
Listings ·
Nasdaq gave Century until February 23, 2026, to lift its closing bid price above $1.00, and moved its listing to the Nasdaq Capital Market. The company's own clinical data for its lead lymphoma program did not meet its bar for a transformational result.
Century Therapeutics (Nasdaq: IPSC) expects to cut headcount by approximately 51% and record about $3.7 million in severance charges. Its CFO and Chief Development Officer will leave in July 2025.
Century Therapeutics, Inc. is a biotechnology company developing allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs) for type 1 diabetes (T1D), other autoimmune diseases and cancer. Its platform combines iPSC differentiation know-how, CRISPR-mediated gene editing, its proprietary Allo-Evasion technology and manufacturing capabilities. Its beta islet, T cell and NK cell programs are built on this platform. CNTY-813 is a beta islet program for T1D, announced in November 2025, which has moved into IND-enabling studies, with an IND submission anticipated as early as 2026. CNTY-308 is a CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases, also in IND-enabling studies, with clinical studies expected to start in 2026 after regulatory authorization. CNTY-101, a CAR-iNK cell therapy with six precision gene edits, is being prioritized in the CARAMEL investigator sponsored trial in B-cell-mediated autoimmune diseases, sponsored by Friedrich-Alexander University Erlangen-Nürnberg. Investigators presented initial CARAMEL data in December 2025.
| Product or program | What it is | Stage |
|---|---|---|
| CNTY-813 | iPSC-derived beta islet cell therapy for type 1 diabetes | IND-enabling studies; IND anticipated as early as 2026 |
| CNTY-308 | CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases | IND-enabling studies |
| CNTY-101 | CAR-iNK cell therapy with six precision gene edits for B-cell-mediated autoimmune diseases | Investigator sponsored trial (CARAMEL), enrolling and dosing |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $109.2 million | $6.6 million |
| Net income (loss) | -$9.6 million | -$126.6 million |
| Cash from operations | -$103.9 million | -$110.1 million |
| Cash and equivalents | $61.9 million | $58.4 million |
| Short-term investments | $55.3 million | $130.9 million |
Century Therapeutics, Inc. trades under the ticker IPSC on NASDAQ.
Century Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Century Therapeutics, Inc. is 1850119. Its filings are on SEC EDGAR.
181,075,321 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Century Therapeutics, Inc. under United States.
Our directory classifies Century Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Century Therapeutics, Inc. is US15673T1007.
aibio.space lists Century Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Century Therapeutics, Inc. is a biotechnology company developing allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs) for type 1 diabetes (T1D), other autoimmune diseases and cancer. Its platform combines iPSC differentiation know-how, CRISPR-mediated gene editing, its proprietary Allo-Evasion technology and manufacturing capabilities.
CNTY-813: iPSC-derived beta islet cell therapy for type 1 diabetes Stage: IND-enabling studies; IND anticipated as early as 2026.
CNTY-308: CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases Stage: IND-enabling studies.
$109.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Century Therapeutics, Inc. reported a net loss of $9.6 million for the fiscal year ended Dec 31, 2025, and used $103.9 million of cash in operations, per its annual report to the SEC.
$119.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio